Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial

OBJECTIVES: To determine whether low-dose spironolactone can safely lower arterial stiffness in patients with chronic kidney disease stage 3 in the primary care setting. DESIGN: A multicentre, prospective, randomised, placebo-controlled, double-blinded study. SETTING: 11 primary care centres in Sout...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMJ Open
Main Authors: Ng, Khai P, Jain, Poorva, Gill, Paramjit S, Heer, Gurdip, Townend, Jonathan N, Freemantle, Nick, Greenfield, Sheila, McManus, Richard J, Ferro, Charles J
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2016
Assuntos:
Renal Medicine
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4769397/
https://ncbi.nlm.nih.gov/pubmed/26916697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2015-010519
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares